ArticleThe Journal of dermatology2026
Assessment of Major Adverse Cardiovascular Event Across Diverse Racial Groups of Psoriasis Patients on Biologic Therapy: A Retrospective Cohort Study.
Article in The Journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Psoriasis is associated with an increased risk of major adverse cardiovascular events (MACE), and biologic therapy may reduce this risk by targeting systemic inflammation. However, limited data exist on whether long term MACE risk differs by biologic class or across racial groups. We conducted a retrospective cohort study to assess the risk of primary MACE in psoriasis patients receiving biological therapies, stratified by biological class, compared with biologic-naïve psoriasis patients. Whether MACE risk among biologic-treated patients varied by race was further examined. After 1:1 propensity score matching, 36 330 biologic-treated patients were compared with 36 330 non-biologic-treated patients. Incident MACE was assessed over 10 years. Class-specific analyses evaluated mutually exclusive biologic exposure groups, including TNF inhibitors (TNFi), IL-17 inhibitors (IL-17i), IL-12/23 inhibitors (IL-12/23i), and IL-23 inhibitors (IL-23i), each compared with an independently matched nonbiologic psoriasis comparator cohort. Race stratified analyses were restricted to biologic-treated patients, with White patients serving as the reference group. Psoriasis patients treated with biologics exhibited a 37% lower hazard of MACE compared with non-biologic users over the 10-year follow-up period [2160 vs. 3294; HR 0.63 (0.60-0.67)]. Class-specific analyses revealed reductions in MACE risk for TNFi [1403 vs. 1844; HR: 0.74 (0.69-0.80)], IL-17i [285 vs. 450; HR: 0.61 (0.53-0.72)], IL-12/23i [280 vs. 374; HR: 0.73 (0.62-0.86)], and IL-23i [238 vs. 363; HR: 0.64 (0.54-0.76)]. Race stratified analyses showed broadly similar MACE risk across racial groups; although, patients identifying as Non-White treated with TNFi did experience a reduced MACE risk compared to White patients [127 vs. 162; HR: 0.79 (0.62-0.99)]. This isolated finding should be interpreted cautiously given multiple race stratified comparisons. Overall, biologic therapy is associated with lower 10-year MACE risk among patients with psoriasis, with findings observed across biologic classes and largely consistent across racial strata.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.